Abstracts tagged "Infection"

Abstract Number: 2618 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in the French Registry Regate (REGISTRY –ROACTEMRA)
Jacques Morel^1,2, Arnaud CONSTANTIN³, Gabriel Baron⁴, Emmanuelle Dernis⁵, Rene-Marc Flipo^6,7, Stephanie Rist Bouillon⁸, Bernard Combe⁹, Jacques-Eric Gottenberg¹⁰, Thierry Schaeverbeke^11,12, Martin Soubrier¹³, Olivier Vittecoq¹⁴, Maxime Dougados¹⁵, Alain Saraux¹⁶, Xavier Mariette¹⁷, Philippe Ravaud¹⁸ and Jean Sibilia¹⁹, ¹Montpellier University Hospital, Montpellier, France, ²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ³Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁴Hôpital Hôtel Dieu, Paris, France, ⁵Service de Rhumatologie, Centre Hospitalier, Le Mans, France, ⁶Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁷Rheumatology, University Hospital, Lille, France, ⁸Rhumatologie, Hopital La Source, La Source, France, ⁹Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Bordeaux University Hospital, Bordeaux, France, ¹²Rheumatology, CHU Bordeaux, Bordeaux, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁵Paris Descartes University, Paris, France, ¹⁶Rheumatology, Brest University Medical School Hospital, Brest, France, ¹⁷Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, ¹⁸Centre d’Épidémiologie Clinique, AP-HP (Assistance Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu, Paris, France, ¹⁹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Observational studies have already reported the risk of serious infections in rheumatoid arthritis (RA) treated with tocilizumab but in limited samples. The aim of…
Abstract Number: 1193 • 2016 ACR/ARHP Annual Meeting
Mortality Rate According to Cause in Patients with Hemophagocytic Lymphohistiocytosis: A Meta-Analysis
Khushboo Sheth^1,2, Chia-Ling Kuo³, Dhruv Modi⁴ and Christopher Scola⁵, ¹Internal Medicine, University of Connecticut, Farmington, CT, Farmington, CT, ²Rheumatology, Stanford University, Palo Alto, CA, ³Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT, ⁴Internal Medicine, Jamaica Hospital and Medical Center, New York, NY, ⁵Rheumatology, Hartford Hospital, Hartford, CT
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome of excessive immune activation associated with high mortality. Early diagnosis and treatment can reduce mortality among these patients.…
Abstract Number: 2620 • 2016 ACR/ARHP Annual Meeting
Retrospective Analysis for Determining the Signs and Symptoms of Infections before They Become Serious in Tocilizumab-Treated RA Patients Using a Postmarketing Adverse Events Reporting Database
Tatsuya Atsumi¹, Yoshiaki Ando², Yukiko Hayashi², Shinichi Matsuda², Riwa Tanaka², Nobuhiro Takagi² and Ayako Nakasone², ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Chugai Pharmaceutical Co. Ltd., Tokyo, Japan
Background/Purpose: Given that tocilizumab (TCZ) directly inhibits IL-6 signaling and strongly suppresses the inflammatory reaction, there is concern that the signs and symptoms associated with…
Abstract Number: 2050 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy
Kevin L. Winthrop¹, Yoshiya Tanaka², Kunihiro Yamaoka³, Jeffrey R. Curtis⁴, Chudy Nduaka⁵, Haiyun Fan⁵, Pinaki Biswas⁶, Tomohiro Hirose⁷, Sriram Krishnaswami⁸, Hernan Valdez⁶, Shigeyuki Toyoizumi⁷, Koshika Soma⁸ and Connie Chen⁶, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Keio University, Tokyo, Japan, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The risk of herpes zoster (HZ) was elevated within the tofacitinib clinical…
Abstract Number: 2251 • 2015 ACR/ARHP Annual Meeting
Current Tobacco Use and the Rates of Postoperative Complications after Total Knee Arthroplasty
Jasvinder A. Singh, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To our knowledge, well-designed studies that have examined the risk of post-arthroplasty implant-related complications after TKA with tobacco use are lacking. Our objective was…
Abstract Number: 2799 • 2015 ACR/ARHP Annual Meeting
Varicella Zoster Reactivation in Patients with Primary Sjögren’s Syndrome and SLE
Eliza F. Chakarvarty¹, Jacy Odell², Astrid Rasmussen³, Kathy L. Sivils², Joel M. Guthridge² and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Increasing data has suggested that individuals with systemic lupus (SLE) are at increased risk of herpes zoster (HZ) reactivation compared to healthy controls and…
Abstract Number: 49 • 2015 ACR/ARHP Annual Meeting
Dose Relationship Between Oral Glucocorticoids and TNF Inhibitors and the Risk of Hospitalized Infectious Events Among Patients with Rheumatoid Arthritis
Neil Accortt¹, Jennifer Schenfeld² and Mona Trivedi³, ¹Amgen, Inc., Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA, ³Rheumatology, Amgen, Thousand Oaks, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for serious hospitalized infectious events (HIEs). Research suggests that tumor necrosis factor alpha inhibitors…
Abstract Number: 2817 • 2015 ACR/ARHP Annual Meeting
The Microbiome of Reactive Arthritis in a Guatemalan Cohort
Alexis Ogdie-Beatty¹, Carles Ubeda², Helga Raquel Garcia Ferrer³, Joan Von Feldt⁴, A Garcia Kutzbach⁵ and Jose U. Scher⁶, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Institute for Research in Public Health, Valencia, Spain, ³Society for Worldwide Med Exchange, North Bay Village, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Internal Medicine, Rheumatology Unit (AGAR), Francisco Marroquin University, School of Medicine, Guatemala City, Guatemala, ⁶Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Reactive arthritis (ReA) is an inflammatory arthritis that typically follows infection. Several agents microbial agents have been implicated, particularly Shigella, Salmonella, Campylobacter in the…
Abstract Number: 566 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Trans-Ancestry Meta-Analysis of Herpes Zoster in RA and Pso Patients Treated with Tofacitinib
Nan Bing¹, HuanYu Zhou¹, BaoHong Zhang¹, John D Bradley², Makoto Nagaoka³, Hernan Valdez⁴, Michael Vincent¹ and James D. Clark¹, ¹Pfizer Inc, Cambridge, MA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Rates of herpes zoster (HZ) were higher than observed with…
Abstract Number: 2851 • 2015 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Associated with an Increase in Serious Infections in Patients with Spondyloarthritis (SpA), Especially during the First 12 Monts of Treatment: Results from the GISEA Registry
Fabiola Atzeni¹, Marco Sebastiani², Valentina Panetta³, Fausto Salaffi⁴, Antonio Marchesoni⁵, Roberta Ramonda⁶, Florenzo Iannone⁷, Roberto Gorla⁸, Elisa Gremese⁹, Marcello Govoni¹⁰, Pier Carlo Sarzi-Puttini¹¹, Gianfranco Ferraccioli¹², Giovanni Lapadula¹³ and on behalf of GISEA group, ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²SC Reumatologia, Dipartimento di Medicine, Medicina d’Urgenza e Specialità Mediche, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, ³L'altrastatistica -Consultancy & Training- Biostatistics office., Rome, Italy, ⁴Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ⁵Day Hospital of Rheumatology, G. Pini Orthopedic Institute, Chair of Rheumatology of Milan, Milan, Italy, ⁶Cattedra, Voc Rheumatology, University of Padua, Padova, Italy, ⁷Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁸Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy, ⁹Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ¹⁰Department of Medical Sciences, UOC of Rheumatology, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, Cona Ferrara, Italy, ¹¹Rheumatology Unit, University Hospital L Sacco, Milan, Italy, ¹²Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹³Bari University, Rheumatology, Bari, Italy
Background/Purpose: Infection is by far the most common and most important adverse effect of TNF inhibitors (TNFI) in the treatment of rheumatoid arthritis (RA) and…
Abstract Number: 674 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Japanese Patients with Reactive Arthritis Induced By Intravesical BCG Therapy for Bladder Cancer: A 19 Years Two-Center Retrospective Study
Hirofumi Nishikawa¹, Yoshinori Taniguchi¹, Takashi Karashima², Tetsushi Aita³, Susumu Nishiyama³, Yasuhiko Yoshinaga³, Yoshitaka Kumon⁴, Yoshiko Shimamura¹, Kosuke Inoue¹, Taro Horino¹, Taro Shuin² and Yoshio Terada¹, ¹Kochi University, Nankoku, Japan, ²Urology, Kochi University, Nankoku, Japan, ³Kurashiki Medical Center, Kurashiki, Japan, ⁴Chikamori Hospital, Kochi, Japan
Background/Purpose: Intravesical instillation of BCG is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive arthritis (ReA)…
Abstract Number: 2899 • 2015 ACR/ARHP Annual Meeting
Mortality Related to Pediatric Systemic Lupus Erythematosus: A Multiple Cause-of-Death Analysis in France
laurent chiche¹, sarah malaekah², alexandre belot³, Brigitte Bader-Meunier⁴, gregoire rey⁵, Noémie Jourde-Chiche Sr.⁶ and mireille eb⁵, ¹internal medicine, Hopital Europeen, Marseille, France, ²pediatry, CHU Lyon, Lyon, France, ³Pediatric Rheumatology, CHU lyon, Hospices Civils de Lyon, HFME, lyon, France, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵cepidc, paris, France, ⁶Nephrology, Aix-Marseille Université - APHM, Marseille, France
Background/Purpose: Although regarded as a disease of adulthood, SLE is also seen in children, and is associated with an increased risk for aggressive clinical course…
Abstract Number: 923 • 2015 ACR/ARHP Annual Meeting
Perceptions of Infectious Risk of Immunosuppressive Medications Among Treating Physicians
Rebecca Sharim¹, Leny Mathew², Michael George³, Preethi Thomas⁴ and Misha Rosenbach⁵, ¹Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Physicians often encounter patients who are treated with immunosuppressive agents and must consider the risk of infection that the medications may pose. We explored…
Abstract Number: 3161 • 2015 ACR/ARHP Annual Meeting
Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus
Candace H. Feldman¹, Francisco M. Marty², Wolfgang C. Winkelmayer³, Hongshu Guan⁴, Jessica M. Franklin⁵, Seoyoung C. Kim⁶, Daniel H. Solomon⁷ and Karen H. Costenbader^8,9, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ³Medicine-Nephrology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Medicine, Division of Rheumatology, Division of Pharmacoepidemiology, Brigham & Women's Hospital, Boston, MA, ⁷Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁸Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are a significant cause of morbidity and mortality in SLE patients. Recent studies show that lupus nephritis patients have more than two-fold higher…
Abstract Number: 1343 • 2015 ACR/ARHP Annual Meeting
Mortality Due to Sepsis in Patients with Rheumatoid Arthritis
Orit Barrett¹, Ella Abramovich², Jacob Dreiher³, Victor Novack⁴ and Mahmoud Abu-Shakra⁵, ¹Department of Medicine D, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, ²Department of Medicine D, Soroka University Medical Center and Ben-Gurion University, Beersheba, Israel, ³Clalit Health Services, Ben-Gurion University of the Negev, Beer Sheva,,, BeerSheba, Israel, ⁴Clinical Research Center, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, ⁵Rheumatic Diseases Unit, Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel
Background/Purpose: Severe infections contribute significantly to the morbidity and mortality of patients with rheumatoid arthritis. The aim of the study was to identify the characteristics…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].